Antibody
- Instrumentos
- Agitadores / Agit. Incubadores
- Orbitales
- Con Incubación
- Incubadores Gran Capacidad
- Lineales, Balanceo y 3D
- Incubadores Microplacas
- Para colocar en estufa
- Magnéticos
- Mezcladores /Roller /Rotatorios
- Agitadores de Paletas
- Jeio Tech Accesorios para Agitadores
- Benchmark Accesorios para Agitadores
- N-Biotek Accesorios para Agitadores
- Biosan Accesorios para Agitadores
- Labnet Int. Accesorios para Agitadores
- Vórtex
- Analisis Imagen, animales, plantas, geles
- Balanzas
- Baños Termostáticos
- Cabinas Flujo / Extraccion gases / PCR
- Centrifugas
- Detectores de Radioactividad
- Electroforesis
- Electroquímica
- Equipos Microplacas
- Espectrofotometros
- Experimentacion Animal
- Hornos de Hibridacion
- Homogeneizadores
- Estufas / Equipos calor, frio
- Luminómetros de Tubos
- Microbiologia
- Pipetas / Dispensadores
- Pipetas Labnet Int. Monocanales Automaticos
- Pipetas HTL Monocanales Automáticas
- Pipeta Accumax Mono y Multicanales
- Pipetas Labnet Int. Multicanales
- Pipetas HTL Multicanales
- Pipetas Volumen Fijo
- Pipetas Electrónicas
- Dispensadores
- Dispensadores de Botella
- Pipetas Biosan Monocanales
- Pipetas Biosan Multicanales
- PCR / Tiempo Real (qPCR)l / Cicladores
- QPCR, Sistemas automaticos
- Sonicadores / Ultrasonidos
- Ultracongeladores
- Bombas Jeringa / Vacio / Osmoticas
- Ultracentrífugas
- Micro Array label free
- Contadores de Células
- Contenedores Criogenicos
- Producción agua ultrapura
- Electrospinning
- Agitadores / Agit. Incubadores
- Reactivos
- Consumibles
- Catálogos PDF
Antibody Hay 184 productos.
Talquetamab
Talquetamab (JNJ-64407564) is a potentially first-in-class humanized IgG4ҡ/λ bispecific antibody that binds to GPRC5D (G-protein-coupled receptor family, group C5, member D) and CD3, and induces T-cell-mediated by T-cell recruitment and activation. killing of GPRC5-expressing MM cells through T cell recruitment and activation.Talquetamab (JNJ-64407564)...
GDC-0853 (Fenebrutinib)
GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK.
Aflibercept
Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
Aflibercept
Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
GDC-0853 (Fenebrutinib)
GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK.
Aflibercept
Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
Aducanumab
Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
Lemzoparlimab
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.
Uliledlimab
Uliledlimab is a potent against CD73 humanized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
Uliledlimab
Uliledlimab is a potent against CD73 humanized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
Bimekizumab
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.
Sirexatamab
Sirexatamab is a monoclonal antibody targeting DKK1.
